Advanced search
Publication Cover
Postgraduate Medicine Volume 130, 2018 - Issue 1
Submit an article Journal homepage
859
Views
13
CrossRef citations to date
0
Altmetric
Clinical Features - Review

Inhalation device options for the management of chronic obstructive pulmonary disease

Michael DePietroMedical Affairs, AstraZeneca LP, Wilmington, DE, USAView further author information
,
Ileen GilbertMedical Affairs, AstraZeneca LP, Wilmington, DE, USAView further author information
,
Lauren A. MilletteMedical Affairs, AstraZeneca LP, Wilmington, DE, USACorrespondence[email protected]
View further author information
&
Michael RiebeInhalation Product Development, AstraZeneca LP, Durham, NC, USAView further author information
Pages 83-97 | Received 18 Aug 2017, Accepted 27 Oct 2017, Published online: 05 Dec 2017

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Arzu Ari, Karen Blain, Said Soubra & Nicola A Hanania. (2021) Treating COPD Patients with Inhaled Medications in the Era of COVID-19 and Beyond: Options and Rationales for Patients at Home. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 2687-2695.
Read now
Nivedita Shetty, David Cipolla, Heejun Park & Qi Tony Zhou. (2020) Physical stability of dry powder inhaler formulations. Expert Opinion on Drug Delivery 17:1, pages 77-96.
Read now
Maureen George & Bruce Bender. (2019) New insights to improve treatment adherence in asthma and COPD. Patient Preference and Adherence 13, pages 1325-1334.
Read now
Edward Kerwin & Gary T. Ferguson. (2018) An overview of glycopyrrolate/eFlow® CS in COPD. Expert Review of Respiratory Medicine 12:6, pages 447-459.
Read now

Articles from other publishers (9)

Sabrina Magramane, Kristina Vlahović, Péter Gordon, Nikolett Kállai-Szabó, Romána Zelkó, István Antal & Dóra Farkas. (2023) Inhalation Dosage Forms: A Focus on Dry Powder Inhalers and Their Advancements. Pharmaceuticals 16:12, pages 1658.
Crossref
Yingjie Chen, Shen Yan, Shengyu Zhang, Quanyi Yin, Xiao Dong Chen & Winston Duo Wu. (2022) Micro-fluidic Spray Freeze Dried Ciprofloxacin Hydrochloride-Embedded Dry Powder for Inhalation. AAPS PharmSciTech 23:6.
Crossref
David M. G. Halpin & Donald A. Mahler. (2022) A Systematic Review of Published Algorithms for Selecting an Inhaled Delivery System in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society 19:7, pages 1213-1220.
Crossref
Ileen Gilbert, Aanam Aslam Mahmood, Katie Devane & Laren Tan. (2021) Association of Nonmedical Switches in Inhaled Respiratory Medications with Disruptions in Care: A Retrospective Prescription Claims Database Analysis. Pulmonary Therapy 7:1, pages 189-201.
Crossref
Jill A. Ohar, Andrea Bauer, Sanjay Sharma & Shahin Sanjar. (2020) In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®. Pulmonary Therapy 6:2, pages 289-301.
Crossref
Maryam Navaie, Carole Dembek, Soojin Cho-Reyes, Karen Yeh & Bartolome R Celli. (2020) Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis. Chronic Respiratory Disease 17, pages 147997311990123.
Crossref
Roberto W. Dal Negro, Paola Turco & Massimiliano Povero. (2019) Patients’ usability of seven most used dry-powder inhalers in COPD. Multidisciplinary Respiratory Medicine 14:1.
Crossref
Aernout van Haarst, Lorcan McGarvey & Sabina Paglialunga. (2019) Review of Drug Development Guidance to Treat Chronic Obstructive Pulmonary Disease: US and EU Perspectives . Clinical Pharmacology & Therapeutics 106:6, pages 1222-1235.
Crossref
Roy A. PleasantsIIII. (2018) Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease. Annals of Pharmacotherapy 53:3, pages 285-293.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.